Reference

Last reviewed: 29 Apr 2026
Sources cited: 10

Compound class334.22 Da

NAD+ precursor (nucleotide; not a peptide)

Nicotinamide mononucleotide — a small-molecule cellular metabolite, not a peptide. Composed of nicotinamide bonded to ribose phosphate. Direct one-step precursor to NAD+ via NMNAT enzymatic conversion. Included in the encyclopedia because it overlaps heavily with the NAD+ longevity stack covered separately.

NMN

Last verified: 2026-04-29

At a glance


Also known as	Nicotinamide mononucleotide, β-NMN, β-nicotinamide mononucleotide
Class	NAD+ precursor (nucleotide; not a peptide)
Typical route	Oral capsule, sublingual tablet, or research-grade powder
Half-life	Plasma NMN half-life ~30 minutes; whole-blood NAD+ elevation persists 60+ days with daily dosing6
Molecular weight	334.22 Da
Sequence / structure	Not a peptide. Nucleotide composed of nicotinamide bonded to ribose phosphate.
UK status	Novel Food classification under FSA review; not yet authorised for general food market sale, though products remain available pending review. Not approved as a medicine.
US status	Lawful as a dietary supplement (FDA reversal, September 2025) after a three-year exclusion (2022–2025) during which FDA classified NMN as “an article authorized for investigation as a new drug” (MIB-626). The 2025 FDA letters to SyncoZymes and Inner Mongolia Kingdomway reinstated NDI eligibility.7 8

What it is

NMN is the direct one-step precursor to NAD+ (nicotinamide adenine dinucleotide), the central coenzyme covered in this encyclopedia’s NAD+ profile. Where NAD+ itself is delivered through IV, subcutaneous, or oral routes (with significant route-dependent bioavailability questions), NMN is orally bioavailable and converts to NAD+ inside cells in a single enzymatic step via NMNAT (nicotinamide mononucleotide adenylyltransferase).

The pharmacological case for NMN over NAD+ supplementation directly is mechanistic and practical:

Oral bioavailability is reliable (~50–60% via the Slc12a8 intestinal transporter discovered in 2019, expressed abundantly in gut, pancreas, liver, and white adipose tissue)
One-step conversion to NAD+ vs nicotinamide riboside (NR), which requires two enzymatic steps
No injection or IV needed, dramatically reducing the cost-per-treatment compared to NAD+ IV protocols
Whole-blood NAD+ elevation is reproducible in multiple human trials at doses of 250–500 mg/day

The biohacker / longevity community uses NMN primarily for NAD+ elevation as an age-related metabolic intervention — the same use case as NAD+ IV but through an oral capsule pathway. The compound exists in a regulatory landscape that has shifted dramatically in 2025: the US went from NMN-banned-as-dietary-supplement (2022) to NMN-lawful-as-supplement (September 2025) with active FDA confirmation. The UK and EU classify NMN as a “novel food” requiring authorisation; products remain available pending review.

It is not a peptide and does not activate the GH/IGF-1 axis. It does not produce the cardiovascular, growth-promoting, or hormonal effects of the GH cluster. Its primary effect is on cellular NAD+ pools, which feeds downstream effects on sirtuin activity, mitochondrial function, DNA repair, and metabolic regulation.

Mechanism

NMN is a substrate for NMNAT (nicotinamide mononucleotide adenylyltransferase), which converts NMN and ATP into NAD+ and inorganic pyrophosphate in a single enzymatic step.1 3

The downstream cascade after cellular NAD+ elevation:

Sirtuin activation — sirtuins (SIRT1, SIRT3, SIRT6) are NAD+-dependent deacetylases implicated in metabolic regulation, mitochondrial biogenesis, and longevity
PARP activation — poly(ADP-ribose) polymerases require NAD+ for DNA-damage response signalling
CD38 substrate dynamics — CD38 is a major NAD+ consumer that increases with age; raising NAD+ helps offset the consumption
Improved insulin sensitivity — particularly in skeletal muscle, demonstrated in the prediabetic-women trial (Yoshino et al., 2021)

The Slc12a8 transporter discovery (2019) explained why NMN has reliable oral bioavailability when other nucleotides don’t: it has its own dedicated active transporter, sodium-dependent and abundantly expressed in gut tissue.

The mechanism is genuinely simple compared to most peptide compounds in this encyclopedia. NMN feeds the NAD+ pool through a one-step conversion. The complexity is downstream — what NAD+ elevation actually does for healthspan and longevity is the open question that the compound’s market is built around.

Routes of administration

Oral capsule (the dominant route)


Bioavailability	~50–60% via the Slc12a8 intestinal transporter
Onset	Plasma NMN peaks ~30 min post-dose; whole-blood NAD+ elevation builds over days; steady state 14 days
Duration	Each dose’s plasma elevation is brief; daily dosing maintains elevated whole-blood NAD+ levels
Typical dose	250–500 mg orally once daily; some protocols use 1,000 mg
Equipment	None — capsule, swallow with water
When this route makes sense	Default. Most clinical evidence and almost all consumer use is oral.

Sublingual


Bioavailability	Some vendors claim higher than oral via direct absorption; not formally compared head-to-head
Typical dose	Same as oral
When this route makes sense	Convenience for users who dislike capsules.

Intranasal

Not supported. NMN is a polar, charged molecule; nasal absorption is unreliable and not standard practice.

Intramuscular / subcutaneous (rare research-chem use)

Some research-chem vendors sell injectable NMN. The injection route bypasses the GI absorption question entirely but introduces sterility, cost, and convenience issues that the oral route doesn’t have. Most users have no reason to inject NMN given that oral works.

Cross-route comparison

Oral is the standard. Sublingual is reasonable for convenience. Injectable exists but offers no clear advantage for most users.

What the evidence says

Honest summary: NMN reliably elevates whole-blood NAD+ levels in human trials. The downstream metabolic effects are documented but modest — improved muscle insulin sensitivity in prediabetic women, generally well-tolerated safety profile, no consistent biomarker improvements beyond NAD+ itself. Long-term outcome data on lifespan, healthspan, or cardiovascular outcomes does not exist.

NAD+ elevation (well-supported)

Multiple human trials have documented NMN’s reliable elevation of whole-blood NAD+ levels:

Yoshino et al., 2021 (Science): 250 mg daily for 10 weeks in prediabetic women, ~25% increase in muscle glucose uptake during hyperinsulinaemia6
Yamashita et al., 2022 (Frontiers in Aging): Multicentre RCT, 250 mg daily, sustained NAD+ elevation over 16 weeks
Pencina et al., 2023: 14-day supplementation with 300 mg/day produced ~2-fold increase in baseline whole-blood NAD+

This is the compound’s strongest evidence claim — it does what it says, oral once-daily, with measurable NAD+ elevation.

Insulin sensitivity (modest support)

The 2021 Science paper from Klein and Imai’s group at WashU showed:

25% increase in muscle glucose uptake during hyperinsulinaemic clamp
No improvement in fasting glucose, blood pressure, lipid profile, hepatic insulin sensitivity, hepatic fat, or inflammation markers

This is a clean, modest positive signal. It’s important to note what the trial did not show — many of the “anti-ageing” claims marketing leans on were not supported in this controlled trial.

Other clinical effects (uncertain)

Smaller trials have explored:

Walking endurance and physical performance in older adults — modest signals, not consistent across trials
Sleep quality — some trials show small improvements, others don’t
Cognitive function — limited evidence; no convincing signal
Cardiometabolic markers — generally no significant effect beyond the muscle-insulin signal

What the evidence does NOT show

No lifespan or healthspan outcome data in humans
No cardiovascular outcomes data
No cancer-prevention data
No comparison data establishing NMN superiority over NR or other NAD+ precursors at controlled doses
No long-term (>16-week) controlled safety data at meaningful sample sizes

The compound’s pharmacology is real and the NAD+ elevation is reliable. The downstream effects biohackers care about — slower ageing, better metabolism, improved cardiovascular health, longer life — are extrapolation from preclinical work and from the modest insulin-sensitivity signal, not direct evidence.

Typical use patterns

Standard supplement protocol

250–500 mg orally once daily, typically morning with or without food
Continuous daily dosing (no cycling)
Typically taken alongside other NAD-axis supports (NR, niacinamide, B-complex) or in NAD-stack formulations
Indefinite duration

High-dose protocol

1,000 mg daily (sometimes split AM/PM)
Used by users targeting maximum NAD+ elevation
The dose-response curve flattens above ~500 mg in the published trial data; 1,000 mg may not produce additional benefit but increases cost and theoretical risk

Sensitive-start protocol

125–250 mg once daily for 2 weeks
Hold before increasing
Most sensitive users find 250 mg sufficient

Stacking

Resveratrol — most common pairing; mechanistic case is sirtuin co-activation. Combined supplements widely available.
TMG (trimethylglycine) — methyl-donor support to offset the methyl-group cost of NAD+ metabolism. Common in NAD-stack formulations.
CoQ10, PQQ, alpha-lipoic acid — mitochondrial support stack additions.
NAD+ IV protocols — some users alternate oral NMN daily with periodic NAD+ IV. Mechanistic case is reasonable; cost-benefit is the open question.
NR (nicotinamide riboside) — same pathway, different precursor. Stacking is mechanistically redundant but some users do it.
GLP-1 agonists, peptides — no documented direct interactions.

Why a user would choose NMN over NAD+ IV

Cost — NMN is dramatically cheaper per month than NAD+ IV protocols (£20–60/month vs £200–500/session)
Convenience — oral capsule daily vs IV infusion
Reliable bioavailability — Slc12a8 transporter ensures consistent absorption

Why a user would choose NAD+ IV over NMN

Larger acute NAD+ elevation per dose (IV bypasses bioavailability ceiling)
Felt effects that some users report from IV are not always replicated from oral NMN
Compressed treatment course — 6-session IV protocol vs months of daily NMN

For sensitive systems

NMN is the best-tolerated compound in this encyclopedia for sensitive-systems users in the longevity-stack space. The mechanism (cellular NAD+ supply) does not produce hormonal, immune, or autonomic effects of the kind that drive sensitive-systems flares for other compounds.

Start dose for sensitive users. 125–250 mg orally once daily for 2 weeks. Hold before considering an increase.

Ramp. If 250 mg is well tolerated, 500 mg is the standard community target. Many sensitive users find 250 mg sufficient indefinitely.

Expected adjustment profile:

Mild flushing — uncommon but reported, presumably nicotinamide-related
Mild nausea or GI changes — uncommon
Subjective energy or sleep changes — variable; some users report subtle improvements in 2–4 weeks, others report nothing

What’s not normal and warrants stopping: persistent GI symptoms, unusual fatigue, headache that doesn’t resolve. These are uncommon but can indicate dose-response issues or product quality issues.

For MCAS / histamine-sensitive users. Generally well-tolerated. The flushing reports are small in number and typically respond to dose reduction. NMN is one of the cleaner compounds in this encyclopedia for this population.

For POTS users. No documented cardiovascular effects at therapeutic doses. Generally well-tolerated.

For UARS / chronic fatigue / ME/CFS. A real population of users reports modest energy/cognition improvements over 4–8 weeks of NMN. The mechanism (NAD+ supply for mitochondrial function) is plausible in this population. Worth a 4–8 week trial; expect modest signals if any.

For active or recent cancer history. Worth specific caution. NAD+ pathway elevation has theoretical implications for tumour-cell metabolism — some cancers depend on NAD+ for proliferation, and NAD+ elevation could theoretically support tumour growth. Pre-clinical data is mixed; some cancer types show concerning patterns, others don’t. Get oncology input before using NMN if you have active or recent cancer. This is the same caution as for NAD+ IV.

For diabetes (type 1 or type 2). Generally safe. The Yoshino trial showed insulin-sensitivity improvements; users with diabetes may see this as beneficial. Monitor as standard.

Interactions worth considering:

NR (nicotinamide riboside) — same pathway; stacking is redundant.
Niacin / nicotinic acid (high dose) — overlapping with the NAD+ pathway; combined effects on lipid profile and flushing are additive.
Methyl-donor supplements (TMG, B12, folate) — supportive; common pairing.
No documented direct interactions with peptides, GLP-1 agonists, or hormonal medications.

Reasonable expectations

Onset. Whole-blood NAD+ elevation is measurable within days; subjective effects, where present, typically appear over 4–8 weeks. Many users report no clear subjective change.

Response rate. Subjective response varies widely. The Yoshino trial showed muscle insulin sensitivity improvement in prediabetic women, but did not show effects on most other markers. Population-level effects are modest at best.

What the evidence actually supports.

Reliable NAD+ elevation — strongly supported
Modest improvement in muscle insulin sensitivity in prediabetic women — directly supported by Yoshino 2021
Generally well-tolerated safety profile — supported across multiple trials

What the evidence does not support.

Lifespan extension claims — speculative
Anti-ageing claims at any specific magnitude — not directly studied
Cognitive enhancement claims — limited and inconsistent evidence
Cardiovascular benefit claims — not directly studied

What not to expect.

Dramatic felt effects. Most users report subtle to no subjective change. The biomarker (NAD+) elevates reliably; whether that translates to meaningful felt effects varies.
Equivalent effects to NAD+ IV protocols. The oral pathway is more sustainable but the per-dose acute NAD+ elevation is smaller.
Effects in users with no NAD+ deficit. Younger, metabolically healthy users may see less benefit than older or insulin-resistant users.

Cost

UK supplement market

NMN is widely available through UK supplement vendors despite the novel-food regulatory uncertainty:

30-day supply at 250–500 mg daily: ~£20–60/month depending on brand and dose
Bulk powder: ~£40–100 for 50 g (typically a 2–6 month supply at 250 mg/day)
Premium brands with third-party testing: ~£60–120/month

US supplement market (post-September 2025 FDA reversal)

NMN is now lawful as a dietary supplement:

Pricing range similar to UK in USD: ~$25–70/month for 250–500 mg daily
Major supplement retailers and longevity-focused vendors carry NMN broadly

Quality variance

The NMN market has documented quality issues — particularly during the 2022–2025 US regulatory grey period when many vendors operated without standard supplement quality oversight. Third-party testing certificates (HPLC purity, contaminant testing) are the meaningful quality marker.

Common quality issues:

Underdosed product (capsules containing less than labelled)
Contamination with niacin or nicotinamide (cheaper related compounds)
Improper storage affecting stability of the unstable NMN molecule

Premium NMN brands ship in dark-glass bottles, often refrigerate-recommend, with explicit batch testing certificates. Cheap NMN in clear plastic bottles is often degraded by the time it reaches the user.

Reconstitution

NMN is a small molecule sold as capsules, sublingual tablets, or powder. It does not require reconstitution. This is a meaningful practical advantage over peptide compounds:

No BAC water
No syringes
No 7-to-28-day reconstituted shelf life
No injection technique to manage

Capsule form: swallow with water. Morning is the dominant convention; some users dose with food, some without — bioavailability differences are small.

Sublingual tablet form: dissolve under the tongue. Allow full dissolution before swallowing.

Powder form: weigh on accurate scale. NMN powder is hygroscopic — exposure to air and moisture degrades it. Store in dry, sealed container, ideally refrigerated.

Storage

Capsules, tablets: room temperature or refrigerated. Manufacturer expiry dates apply. Premium brands typically recommend refrigeration.
Powder: refrigerate, sealed with desiccant. NMN is unstable at room temperature with humidity exposure.
Avoid heat — NMN degrades above ~25°C with prolonged exposure.

What gets miscalculated

Buying cheap NMN. The market has substantial quality variance. Cheap product is often degraded or underdosed. Third-party test certificates matter.
Storing at room temperature. NMN is more thermolabile than typical supplements; refrigeration extends shelf life.
Stacking redundantly with NR. Same pathway, different precursor. Stacking offers no clear benefit.
Comparing NMN to NAD+ IV directly. Oral NMN at any dose produces less acute NAD+ elevation than IV. The comparison should be NMN vs NR (oral precursors) rather than NMN vs IV.

Areas of concern ⚠

Cancer / NAD+ pathway concern

This is the most important caution. NAD+ is required by both healthy and cancer cells; some cancers are NAD+-dependent and NMN supplementation could theoretically support tumour growth. The preclinical evidence is mixed:

Some studies suggest NAD+ elevation supports anti-tumour immunity
Other studies suggest NAD+ elevation supports tumour-cell metabolism

Treat as a cautionary contraindication for users with active malignancy or recent cancer treatment. The mechanism is plausible enough that erring cautiously is appropriate; ask oncology input before using NMN in cancer survivorship contexts.

Long-term safety beyond ~16 weeks is uncharacterised

The longest published controlled trials are 16–24 weeks. Multi-year safety in healthy users is not characterised. The mechanistic concerns are minimal at typical supplement doses, but cumulative effects of sustained NAD+ pool elevation over years are not directly studied.

Quality and sourcing — the largest practical concern

The 2022–2025 US regulatory grey period accelerated quality issues in the NMN market that are still resolving. Many vendors operated without standard quality oversight. Third-party batch testing is the meaningful quality marker. Premium brands typically publish HPLC purity testing per batch.

The compound is also intrinsically unstable — heat, humidity, and air exposure all degrade NMN. Cheap NMN in clear plastic bottles stored at room temperature is often substantially degraded by the time it reaches the user. Premium brands ship in dark glass with refrigeration recommendations.

Methylation cost

NMN metabolism uses methyl groups (one of the steps that produces 1-methylnicotinamide as a metabolite). Users with methylation issues (MTHFR variants, low B-vitamin status, heavy alcohol use) may benefit from supplemental TMG (trimethylglycine), B12, and folate alongside NMN to support methylation capacity. Without methyl-donor support, sustained high-dose NMN can theoretically deplete methylation cofactors.

Populations where NMN is contraindicated or high-risk

Active malignancy or recent cancer treatment (relative contraindication; oncology input needed)
Pregnancy and breastfeeding — no safety data
Under 18 — not studied in this population; no clear use case
Severe renal or hepatic impairment — limited data; caution warranted

What the community gets wrong

“NMN reverses ageing.” The Yoshino trial showed muscle insulin sensitivity improvement in prediabetic women. It did not show ageing reversal. The “reverse ageing” framing is marketing, not trial data.
“Higher doses always work better.” The dose-response curve flattens around 500 mg; going to 1,000 mg+ may not provide additional benefit and increases cost.
“NMN is a peptide.” It’s a nucleotide. Some marketing materials conflate it with peptide therapeutics; mechanistically it’s a cellular metabolite precursor, not a peptide drug.
“NMN and NR are the same thing.” Same pathway, different molecules, different transport mechanisms. Choose one based on cost and tolerance; stacking is redundant.

FDA / regulatory status

Jurisdiction	Status	Last verified
US (FDA)	Lawful as a dietary supplement following FDA reversal in September 2025. NMN was previously excluded from the dietary supplement definition (November 2022 – September 2025) due to FDA’s IND classification. SyncoZymes (NDIN 1247) and Inner Mongolia Kingdomway (NDIN 1259) have both received FDA letters confirming reinstated NDI eligibility.7 8	2026-04-29
UK (FSA)	Novel Food classification under review. Not yet authorised for general food market sale. Products remain available pending review.	2026-04-29
EU (EFSA)	Novel Food classification under review.	2026-04-29
Australia (TGA)	Listed in therapeutic goods with specific permitted use cases. Australia has been more permissive of NMN than other jurisdictions.	2026-04-29
WADA (sport)	Not prohibited. NMN is a vitamin precursor and not on the prohibited list.	2026-04-29

Narrative. NMN’s regulatory pathway has moved more dramatically than any compound in this encyclopedia in 2025. The US FDA reversal in September 2025 ended a three-year exclusion and reinstated NMN as a legal dietary supplement; UK and EU continue Novel Food review with products remaining on shelves. For most consumers, NMN is now broadly accessible across major Western markets, with the regulatory uncertainty largely behind it. The legitimacy gap between NMN (a regulated supplement) and peptide compounds in this encyclopedia (research chemicals or pharmaceuticals only) is the largest in the encyclopedia.

What to track in Peptrax

Two NMN capsules labelled “500 mg” can contain materially different actual NMN content — the supplement market grew faster than its quality oversight, and the 2022–2025 US regulatory grey period made it worse. For NMN specifically, the brand and batch are protocol variables, not just metadata: a user who feels nothing on one product and clear effects on another is usually seeing product-source variance, not biological non-response.

For most users, the highest-signal log is subjective energy and sleep changes over 4–8 weeks of dosing — daily 1–5 ratings of energy, sleep depth, and morning alertness. NAD+ blood testing is available privately if desired but is expensive; for most users the subjective trend is the practical alternative.

For sensitive-systems users, the priority log is the first 2–4 weeks: any GI symptoms, unusual fatigue, headache. NMN is well-tolerated for most users in this population, but the small fraction who don’t tolerate it identify the issue early.

Across all users, logging methylation support (TMG, B-complex, B12, folate) alongside NMN matters. The methylation cost of NMN metabolism is modest at typical doses but can accumulate. If energy or cognition improves on NMN, then plateaus or worsens at the same dose, methylation support is a frequent missing piece.

For personal tracking and informational purposes only — not medical advice.

NMN